US Bancorp DE Buys 118 Shares of Laboratory Co. of America Holdings (NYSE:LH)

US Bancorp DE grew its stake in Laboratory Co. of America Holdings (NYSE:LH) by 0.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,421 shares of the medical research company’s stock after acquiring an additional 118 shares during the quarter. US Bancorp DE’s holdings in Laboratory Co. of America were worth $5,142,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of LH. FMR LLC increased its stake in shares of Laboratory Co. of America by 17.0% in the 3rd quarter. FMR LLC now owns 1,586,397 shares of the medical research company’s stock valued at $354,528,000 after acquiring an additional 230,708 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Laboratory Co. of America by 9.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,930,395 shares of the medical research company’s stock valued at $431,405,000 after acquiring an additional 167,137 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Laboratory Co. of America by 22.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 577,189 shares of the medical research company’s stock valued at $128,990,000 after acquiring an additional 105,443 shares during the last quarter. Proficio Capital Partners LLC bought a new stake in Laboratory Co. of America during the 4th quarter worth approximately $16,512,000. Finally, Nordea Investment Management AB increased its stake in Laboratory Co. of America by 7.0% during the 4th quarter. Nordea Investment Management AB now owns 1,052,927 shares of the medical research company’s stock worth $243,321,000 after purchasing an additional 68,974 shares in the last quarter. 95.94% of the stock is owned by institutional investors.

Insider Activity

In other Laboratory Co. of America news, CEO Adam H. Schechter sold 6,121 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $244.62, for a total transaction of $1,497,319.02. Following the completion of the sale, the chief executive officer now owns 86,445 shares of the company’s stock, valued at $21,146,175.90. This trade represents a 6.61 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kerrii B. Anderson sold 1,000 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $235,000.00. Following the sale, the director now directly owns 12,722 shares of the company’s stock, valued at $2,989,670. This represents a 7.29 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,000 shares of company stock valued at $3,449,757. 0.85% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on LH. Bank of America increased their target price on Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Morgan Stanley increased their target price on Laboratory Co. of America from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Piper Sandler increased their target price on Laboratory Co. of America from $240.00 to $260.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Jefferies Financial Group increased their target price on Laboratory Co. of America from $275.00 to $290.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Finally, Barclays lowered their target price on Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating for the company in a research note on Friday, February 7th. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $268.38.

Laboratory Co. of America Trading Down 1.0 %

NYSE LH opened at $254.31 on Thursday. The company has a market cap of $21.29 billion, a PE ratio of 28.83, a PEG ratio of 1.71 and a beta of 1.07. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67. Laboratory Co. of America Holdings has a 12 month low of $191.97 and a 12 month high of $258.59. The stock has a 50 day moving average of $242.77 and a 200-day moving average of $233.34.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. On average, equities research analysts anticipate that Laboratory Co. of America Holdings will post 16.01 EPS for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.13%. The ex-dividend date is Thursday, February 27th. Laboratory Co. of America’s payout ratio is presently 32.65%.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.